


Neocryptotanshinone

Cat. No.:	HY-119720
CAS No.:	109664-02-0
Molecular Formula:	C ₁₉ H ₂₂ O ₄
Molecular Weight:	314.38
Target:	NF-κB; NO Synthase
Pathway:	NF-κB; Immunology/Inflammation
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (318.09 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		3.1809 mL	15.9043 mL	31.8086 mL
	5 mM		0.6362 mL	3.1809 mL	6.3617 mL
	10 mM		0.3181 mL	1.5904 mL	3.1809 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Neocryptotanshinone, a fatty diterpenoids from *Salvia Miltiorrhiza*, inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathways^{[1][2]}.

IC₅₀ & Target

iNOS

In Vitro

Neocryptotanshinone exhibits anti-inflammatory effect by suppression of NF-κB and iNOS signaling pathways^[1]. Neocryptotanshinone (10 μM and 20 μM, 24 h) inhibits LPS-induced iNOS protein expression in RAW264.7 cells^[1]. Neocryptotanshinone (20 μM, 24 h) shows no obvious cytotoxic effect towards murine RAW264.7 macrophages^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay^[1]

Cell Line: RAW264.7 cells

Concentration: 5, 10 and 20 μM

Incubation Time: 24 hours

	Result:	Inhibited LPS-induced cell viability in a dose-dependent manner.
	Western Blot Analysis ^[1]	
	Cell Line:	RAW264.7 cells
	Concentration:	20 μ M
	Incubation Time:	24 hours
	Result:	Inhibited LPS-induced activation of NF- κ B pathway and down-regulated LPS-induced expression of p-NF- κ B p65, p-I κ B α and p-IKK β .
In Vivo	Neocryptotanshinone causes reversals of decreased pain thresholds induced by MSU treatment after 30, 60, and 120 min S. miltiorrhiza Bunge extract treatment (contains single active components) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	MSU-induced pain model in male ICR mice (weighing 20-25 g) ^[2]
	Dosage:	10, 25, 50 or 100 mg/kg
	Administration:	Oral gavage; for 30, 60, 120 min
	Result:	Inhibited inflammatory symptoms and nociceptive behaviors in a dose-dependent manner.

REFERENCES

[1]. FENG Jinghui, et al. Effects of Salvia miltiorrhiza Bunge extract and its single components on monosodium urate-induced pain in vivo and lipopolysaccharide-induced inflammation in vitro. *J Tradit Chin Med.* 2021. 41(2): 219-226.

[2]. Chuanhong Wu, et al. Neocryptotanshinone Inhibits Lipopolysaccharide-Induced Inflammation in RAW264.7 Macrophages by Suppression of NF- κ B and iNOS Signaling Pathways. *Acta Pharm Sin B.* 2015 Jul;5(4):323-9.

[3]. H C Lin, et al. Two New Fatty Diterpenoids From Salvia Miltiorrhiza. *J Nat Prod.* 2001 May;64(5):648-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA